Meropenem Steriscience

Meropenem, the active ingredient in Meropenem Steriscience, is a carbapenem presented as an injection for intravenous use. It is indicated for the treatment of severe bacterial infections, including complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired and ventilator‑associated pneumonia, meningitis, and sepsis in hospitalized adults.

GNH USA supplies Meropenem Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with support for regulatory compliance, cold‑chain logistics where required, and reliable global distribution.

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections affecting various organ systems.

Complicated intra‑abdominal infections: provides broad‑spectrum coverage to eradicate Gram‑negative, Gram‑positive and anaerobic pathogens. Complicated urinary tract infections: achieves rapid bacterial clearance in resistant uropathogens. Hospital‑acquired pneumonia: delivers effective therapy against multidrug‑resistant organisms. Ventilator‑associated pneumonia: penetrates lung tissue to treat severe ventilator‑related infections. Meningitis: attains therapeutic concentrations in cerebrospinal fluid for bacterial meningitis. Sepsis: offers rapid bactericidal activity in systemic infections.

Adverse reactions reported with meropenem may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional post‑infusion emesis. - Headache: transient cranial discomfort. - Infusion site reactions: erythema or phlebitis at the injection site. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile infection: severe colitis risk. - Anaphylaxis: acute hypersensitivity reaction. - Stevens‑Johnson syndrome: rare severe skin eruption. - Renal toxicity: acute kidney injury in susceptible individuals. - Neutropenia: marked reduction in white blood cells.

Meropenem should be used with caution in specific clinical situations.

Renal impairment: adjust dose according to creatinine clearance. Hypersensitivity: avoid in patients with known carbapenem or β‑lactam allergy. Pregnancy: category B; weigh benefits against potential risks. CNS disorders: monitor for seizures in patients with epilepsy or brain injury. C. difficile risk: monitor for signs of colitis during and after therapy. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: carbapenems can reduce serum valproate levels, risking seizure breakthrough. - High‑dose aminoglycosides: combined nephrotoxicity may be additive. - Loop diuretics: may increase risk of renal dysfunction.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation. - Oral contraceptives: possible reduced effectiveness, advise backup method. - Other β‑lactam antibiotics: antagonistic effect, avoid concurrent use. - Diuretics: monitor electrolytes and renal function.